Aptocine™

Development Pipeline

LSO is focusing on a number of cancers for the initial development of Aptocine™: Hepatoma, Metastatic Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Lung Cancer, Nasopharyngeal Cancer, Head and Neck Cancer, Kidney Cancer, and Glioma/Glioblastoma. Aptocine is also in Phase 2 development for treatment of Benign Prostatic Hyperplasia (BPH), and preclinical development for other non-cancer indications.

View the pipeline


Current Clinical Trials

LSO has completed treatment in a Phase 3 trial in hepatocellular carcinoma and is currently enrolling patients in a Phase 3 trial in colorectal cancer metastatic to the liver, as well as a Phase 2 trial in benign prostatic hyperplasia (BPH).

Learn more

Publications

  • Bromley E, Owczarczak, Keltner L, Wang S, Gollnick SO: Characterization of an anti-tumor immune response after light-activated drug therapy using talaporfin sodium in a spontaneously metastasizing mammary tumor model. 2009 ASCO Annual Meeting. J Clin Oncol. May 20 suppl: abstract 3052.
  • Wang S, Keltner L, Winship MJ, Lee W: A phase 1/2 safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma. 2009 ASCO Annual Meeting: Abstract e15684.
  • Keltner L, Chen JC, Wang S., Rakić, ML: A phase 2a study of light-activated talaporfin sodium in patients with primary or recurrent glioblastoma multiforme. 2009 ASCO Annual Meeting: Abstract e13026.
  • Marks LS, Macairan M, Keltner L, Christophersen J, Briggs B, Wang S, et al.: Light-Activated Drug Therapy for BPH. American Urological Association Annual Meeting 2009: Abstract 92948.
  • Morgan T, Nguyen H, Dalos M, Christophersen J, Chen J, Corey E, et al.: Litx with talaporfin sodium (LS11) in prostate cancer xenografts. 9th Annual SUO Winter Meeting 2008: Poster #6.
  • Christophersen J, Winship MJ, Keltner L, Wang SS: Light-activated drug therapy in canine prostate. 2008 ASCO Annual Meeting. J Clin Oncol. May 20 suppl; abstr 14671.
  • Kujundzic M, Vogl TJ, Stimac D, Rustemovic N, Hsi RA, Roh M, et al. A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer. J Surg Oncol 2007;96(6):518-24.
  • Winship MJ, Wang S-S, Chen JC, Keltner L, Christophersen JS: Treatment of colorectal liver metastases using talaporfin sodium and intratumoral placement of LEDs. 2005 ASCO Annual Meeting 2005; 23 (16s, Part I of II):286s (abstract 3663).
  • Xu H, Liang Y, Krouse M, Kylstra JW, Winship J, Chen JC, et al.: Ablation of liver tumors with novel light activated drug-device technology (Litx): Targeting feeding vessels may permit killing of larger tumor volumes. Gastrointestinal Cancers Symposium 2005:143 (poster abstract 21).
  • Lustig RA, Vogl TJ, Fromm D, Cuenca R, Alex Hsi R, D'Cruz AK, Krajina Z, Turic M, Singhal A, Chen JC. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer 2003;98(8):1767-71.
  • Chen J, Keltner L, Christophersen J, Zheng F, Krouse M, Singhal A, et al. New technology for deep light distribution in tissue for phototherapy. Cancer J 2002;8(2):154-163.